uploads/2018/06/immunology.png

An Update on Johnson & Johnson’s Immunology Business

By

Updated

Immunology business’s revenue trends

In the first quarter, Johnson & Johnson’s (JNJ) Immunology business generated revenues of $3.0 billion compared to $2.9 billion in the first quarter of 2017, which reflected ~3.8% YoY (year-over-year) growth.

In the first quarter, Johnson & Johnson’s Immunology business generated revenues of $2.0 billion and $1.0 billion from the US and international markets, respectively, reflecting an ~5.8% YoY decline and ~29.0% YoY growth.

Article continues below advertisement

Remicade and Simponi: Revenue trends

Johnson & Johnson’s Remicade generated revenues of $1.4 billion in the first quarter compared to $1.7 billion in the first quarter of 2017, which reflected an ~17.0% YoY decline.

Remicade generated first-quarter revenues of $916.0 million and $331.0 million from sales in the US and international markets, respectively, compared to $1.1 billion and $325.0 million in the first quarter of 2017. This represents an ~22.5% decline and 1.8% growth on a YoY basis.

Johnson & Johnson’s Simponi reported revenues of $518.0 million in the first quarter compared to $428.0 million in the first quarter of 2017, which is ~21.0% YoY growth.

In the US and international markets, Simponi generated first-quarter revenues of $224.0 million and $294.0 million, respectively, compared to $229.0 million and $199.0 million in the first quarter of 2017. This represents an ~2.2% decline and 47.7% growth on a YoY basis.

Stelara’s revenue trends

Stelara reported net revenues of $1.1 billion in the first quarter compared to $823.0 million in the first quarter of 2017, reflecting ~28.9% YoY growth. Stelara generated first-quarter revenues of $652.0 million and $409.0 million from its sales in the US and international markets, respectively, which is ~19.2% and ~48.2% growth on a YoY basis.

Stelara is used to treat moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn’s disease. Stelara’s peers Novartis’s (NVS) Cosentyx and Eli Lilly’s (LLY) Taltz reported first-quarter revenues of $580.0 million and $147.0 million, respectively.

Advertisement

More From Market Realist